Charles River Labs reiterates FY26 revenue and non-GAAP earnings outlook, guides FY30 organic growth of 5-7%

Charles River Laboratories International reiterated its FY26 revenue and non-GAAP earnings outlook and said it expects FY30 organic revenue growth in the range of 5% to 7%, disclosed at its investor day.

Detected & updated continuously · Source: Nebula